Evidence map›Paper›PMID 36901759›Full record

ArticleInternational journal of molecular sciences2023

Accelerating the Discovery of Anticancer Peptides through Deep Forest Architecture with Deep Graphical Representation.

Lantian Yao, Wenshuo Li, Yuntian Zhang, Junyang Deng, Yuxuan Pang, Yixian Huang, Chia-Ru Chung, Jinhan Yu, Ying-Chih Chiang, Tzong-Yi Lee

Full text read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Explainable Artificial Intelligence in the Field of Drug Research.Drug design, development and therapy · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Natural Anticancer Molecules and Their Therapeutic Potential.International journal of molecular sciences · 2023
    Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lantian YaoKobilka Institute of Innovative Drug Discovery, School of Medicine, The Chinese University of Hong Kong (Shenzhen), 2001 Longxiang Road, Shenzhen 518172, China.ORCID 0000-0003-4554-6827
Wenshuo LiSchool of Science and Engineering, The Chinese University of Hong Kong (Shenzhen), 2001 Longxiang Road, Shenzhen 518172, China.
Yuntian ZhangWarshel Institute for Computational Biology, School of Medicine, The Chinese University of Hong Kong (Shenzhen), 2001 Longxiang Road, Shenzhen 518172, China.
Junyang DengSchool of Medicine, The Chinese University of Hong Kong (Shenzhen), 2001 Longxiang Road, Shenzhen 518172, China.
Yuxuan PangSchool of Science and Engineering, The Chinese University of Hong Kong (Shenzhen), 2001 Longxiang Road, Shenzhen 518172, China.ORCID 0000-0002-6778-7034
Yixian HuangWarshel Institute for Computational Biology, School of Medicine, The Chinese University of Hong Kong (Shenzhen), 2001 Longxiang Road, Shenzhen 518172, China.
Chia-Ru ChungKobilka Institute of Innovative Drug Discovery, School of Medicine, The Chinese University of Hong Kong (Shenzhen), 2001 Longxiang Road, Shenzhen 518172, China.ORCID 0000-0002-4548-7620
Jinhan YuWarshel Institute for Computational Biology, School of Medicine, The Chinese University of Hong Kong (Shenzhen), 2001 Longxiang Road, Shenzhen 518172, China.
Ying-Chih ChiangKobilka Institute of Innovative Drug Discovery, School of Medicine, The Chinese University of Hong Kong (Shenzhen), 2001 Longxiang Road, Shenzhen 518172, China.ORCID 0000-0002-1585-7213
Tzong-Yi LeeWarshel Institute for Computational Biology, School of Medicine, The Chinese University of Hong Kong (Shenzhen), 2001 Longxiang Road, Shenzhen 518172, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is one of the leading diseases threatening human life and health worldwide. Peptide-based therapies have attracted much attention in recent years. Therefore, the precise prediction of anticancer peptides (ACPs) is crucial for discovering and designing novel cancer treatments. In this study, we proposed a novel machine learning framework (GRDF) that incorporates deep graphical representation and deep forest architecture for identifying ACPs. Specifically, GRDF extracts graphical features based on the physicochemical properties of peptides and integrates their evolutionary information along with binary profiles for constructing models. Moreover, we employ the deep forest algorithm, which adopts a layer-by-layer cascade architecture similar to deep neural networks, enabling excellent performance on small datasets but without complicated tuning of hyperparameters. The experiment shows GRDF exhibits state-of-the-art performance on two elaborate datasets (Set 1 and Set 2), achieving 77.12% accuracy and 77.54% F1-score on Set 1, as well as 94.10% accuracy and 94.15% F1-score on Set 2, exceeding existing ACP prediction methods. Our models exhibit greater robustness than the baseline algorithms commonly used for other sequence analysis tasks. In addition, GRDF is well-interpretable, enabling researchers to better understand the features of peptide sequences. The promising results demonstrate that GRDF is remarkably effective in identifying ACPs. Therefore, the framework presented in this study could assist researchers in facilitating the discovery of anticancer peptides and contribute to developing novel cancer treatments.

Indexed as

NeoplasmsPeptidesAlgorithmsAmino Acid SequenceHumansNeural Networks, ComputerPeptidesanticancer peptidedeep forestdrug discoveryfeature extractionsequence analysis

Identifiers

PMID36901759
PMCPMC10001941

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read41
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.